Tenthpin, a Swiss life-sciences boutique, inaugurated an “AI, IoMT-based” life-sciences innovation hub in Bengaluru’s Koramangala on 18 September. The release promises advanced-therapy digital solutions, a doubled team within two years, and collaboration with local research institutions. It names no clients, no products, no investment figure and no current headcount. Here is what the announcement says, what the record shows, and what nobody asked.
What the Tenthpin Announcement Says
The hub sits at Global Tech Park. Founder Juergen Bauer inaugurated it, with co-founder Michael Schmidt and India head Sachin Bhure present. Focus areas: AI, the Internet of Medical Things, Advanced Therapy Medicinal Products (ATMPs) and intelligent clinical supply chain.
The pitch
The centre will develop “AI-powered analytics, predictive modelling and cloud-based collaboration tools”. These speed gene, cell and tissue treatments from research to market. Schmidt’s quote grounds it in SAP: Batch Release Hub, Intelligent Clinical Supply Management and Advanced Therapy Orchestration. Bhure adds the only number in the release — a plan to double the Bengaluru team within two years.
The framing
Bauer calls the office “an investment in the future of Life Sciences innovation”. He credits Indian talent as the cornerstone of the global delivery model. The release also promises collaboration with “local research institutions, universities and industry partners” — none named. The About section claims 16 of the top 20 global pharma companies as clients.
The Company Behind the Tenthpin Hub
This is not a startup. Former SAP life-sciences executives founded the firm in Basel in January 2017. It runs as a pure-play SAP consultancy for pharma, biotech, medtech and animal health.
LinkedIn data puts headcount near 500, growing about 7% a year. India is the largest country at roughly 109 people — about a fifth of the firm. Revenue estimates fall in the $100-150 million range.
The SAP DNA
The firm’s real distinction is co-development. It helped build SAP Batch Release Hub, SAP Intelligent Clinical Supply Management and SAP’s Cell and Gene Treatment Orchestration products. SAP has recognised it as a Life Sciences Partner of the Year under its Diamond Initiative. Strip the AI framing away and the Bengaluru hub is a delivery centre for regulated-industry SAP work. Its specialism is the software that orchestrates advanced therapies.
A claim worth checking
The release says 16 of the top 20 global pharma companies work with Tenthpin. A third-party partner profile reports 12 of the top 20 and 70-plus clients overall. Both cannot be current at once. The firmer number is unattributed either way; treat the client-count claim as company-reported.
The India ATMP Boom Behind the Tenthpin Hub
The tailwind is real, and Bengaluru sits at its centre. India approved its first indigenous CAR-T therapy, NexCAR19, in October 2023. IIT Bombay, Tata Memorial Centre and ImmunoACT developed it. The price: around ₹40-50 lakh, against Western costs of $400,000-700,000.
Immuneel Therapeutics of Bengaluru launched India’s second CAR-T, Qartemi, in January 2025. It runs the country’s first GMP CAR-T plant.
The market math
India’s cell and gene therapy market stands near $818 million in 2025 and projects to $2.7 billion by 2034. Analysts expect the supporting CDMO segment to grow at nearly 25% annually through 2033. India still holds under 3% of the global CGT CDMO market. Two CAR-T products are approved domestically, and treatment capacity concentrates in a few metros.
Why the timing works
Every therapy in that chain needs batch release, clinical supply, chain-of-identity and orchestration software. Those are exactly the SAP products this consultancy co-develops. A 2026 amendment consolidating central licensing for cell and gene products is pushing Indian developers toward compliant, scalable systems. The allogeneic “off-the-shelf” shift ahead multiplies that software demand. The hub makes commercial sense even if the release never says so.
New vs Repackaged: What the Release Delivers
Genuinely new — a facility and a pledge. A physical hub and a commitment to double an undisclosed team within two years. For a 500-person firm, that is meaningful if it happens.
Repackaged — the AI framing. The AI, IoMT and “next-generation capabilities” language wraps around existing SAP delivery strengths. The release describes capabilities the firm already sells globally.
Absent — everything measurable. No product launches, no client commitments, no investment figure, no base headcount, no named research partners. The release measures intent, not output.
The Questions the Press Release Doesn’t Answer
How big is the Bengaluru team today? “Double the current team” is a pledge without a denominator. From 50 people it means one thing; from 200, another.
What is the investment? An office opening without a capital number is a leasing decision, not a strategy disclosure.
Which research institutions? Collaboration with unnamed universities is a standard sentence. Bengaluru has real candidates — Immuneel, the biotech parks, the academic hospitals — none acknowledged.
What are the “GxP-ready AI solutions”? The phrase appears twice without a product name, capability list or availability date.
Who are the clients? Sixteen of the top 20 pharma companies allegedly work with the firm. Zero are named, and no India-market client appears anywhere.
What does India deliver versus sell? The release celebrates Indian talent for global delivery. It says nothing about serving Indian pharma — the companies actually building the ATMP boom the hub invokes.
What This Means for You
If you run a life-sciences SAP landscape, the hub deepens a specialist’s delivery capacity in your time zone. The co-developed ATMP and clinical-supply products are the substance here; evaluate the AI ambitions when they ship as named offerings.
If you build ATMPs in India, note that global specialists are assembling your industry’s software layer around you. Chain-of-identity, batch release and orchestration systems decide whether manufacturing scales. Local presence makes a niche firm more accessible than a Big Four practice.
If you track India’s GCC story, this is a quieter variant of it. A 500-person Swiss boutique already runs a fifth of its workforce in India. Its India headcount is growing faster than the firm overall. The “Innovation Hub” is the branding catching up to a delivery dependency that has existed for years.
Tenthpin: Editor’s Note
This article draws on the press release of 18 September 2026. It supplied hub details, executive quotes, focus areas, the client-count claim and the doubling pledge.
Verified from public sources: Tenthpin’s founding, Basel headquarters, SAP co-development record and country footprint come from partner profiles and the Swiss commercial register. Headcount, growth and India workforce share come from LinkedIn company data; the revenue range comes from a third-party profile. India ATMP context comes from BioSpectrum white papers, Grand View Research data, industry reporting and peer-reviewed literature. Sources cover the NexCAR19 and Qartemi approvals, pricing, Immuneel’s facility, market projections and the 2026 licensing amendment.
Company-reported and unverified: the 16-of-top-20 client claim (a partner profile says 12). The current Bengaluru team size and the hub investment are likewise unstated. Market projections carry their publishers’ methodologies and assumptions.